Introduction
Tuberculosis (TB) is the most frequent life-threatening opportunistic disease in people living with HIV (PLHIV) in the first 3 months of antiretroviral treatment (ART), in both industrialized and resource-constrained settings [1, 2] . ART significantly but not entirely reduces the risk of TB disease [3] . It is also associated with significantly increased mortality both before and during ART [4] [5] [6] . Morbidity and mortality from drug-sensitive and drug-resistant TB among PLHIV are unacceptably high [7, 8] . For all these reasons regular screening of all PLHIV for active TB disease and provision of either treatment for active disease or preventive therapy, and the provision of earlier ART [9] along with other measures to minimise TB transmission are essential.
The World Health Organization (WHO) recommended regimen for TB preventive therapy in adolescents and adults living with HIV is isoniazid [isonicotinic acid hydrazide (INH)] 300 mg daily for at least 6 months [10] [11] [12] [13] . Assessment of the duration of isoniazid preventive therapy (IPT) detected no significant difference in efficacy between 6 and 12 months [14] . Although 9 months of IPT is supported by evidence and recommended in some guidelines, there are no studies that have directly compared it either with 6 or 12 months of IPT. Two trials from Botswana [15] and South Africa [16] suggested increased benefit with 36 months or longer duration of IPT than with a 6-month regimen, particularly in people who have a positive tuberculin skin test (TST). However, no difference in benefit was observed between a 6-month and 36-month duration IPT in a clinical trial that was conducted in India [17] .
In children living with HIV and presenting with or without positive TST, IPT was shown to reduce early mortality by 50% and incidence of TB by 70% in a small, randomized trial where ART was not widely available [18] . However, clinical trials in adults have shown no survival benefit of IPT [19] [20] [21] [22] , although one cohort study showed a survival advantage [23] . In all studies, isoniazid was generally safe and well tolerated [20] .
In 1993, the WHO first issued a policy statement that recognized the efficacy of TB preventive therapy and recommended targeting IPT in PLHIV [10, 24, 25] . That was also the year when TB was declared a global emergency [26] . It was also packaged as one of the 12 collaborative TB/HIV activities recommended by WHO [10] and repackaged as part of the Three 'I's for HIV/TB (isoniazid preventive treatment, infection control for TB, and intensified case finding) in 2008 [27] . It also revised its policy on IPT in 2010 reiterating the importance of IPT as a core function of services provided to PLHIV and as a primary responsibility of National AIDS Programs.
The purpose of this article is to discuss the global progress in the implementation of IPT as a public health intervention between 2002 and 2009, and to review critical health system barriers for its nationwide implementation. It offers simplified strategies and critical steps that are essential to scale up its implementation in high HIV prevalence countries.
Methods
We used the existing WHO systems of data collection to present the progress of implementation of collaborative HIV/TB activities. The system relies on information provided by countries to WHO through its global TB monitoring and evaluation system [28] . Data on collaborative TB/HIVactivities are also collected through the joint data collection system of WHO, United Nations Children's Fund, and Joint United Nations Program on HIV/AIDS (UNAIDS) as part of the system that monitors and reports on progress in the health sector response toward universal access of HIV/AIDS services [29] . We used a combination of systematic review, document analysis and global expert opinion to present the barriers for scaling up of IPT implementation. We searched PubMed for combinations of the search terms 'isoniazid', 'prophylaxis' or 'prevention' with 'HIV', 'tuberculosis', 'challenges', and 'barriers'. We considered publications in English with no limit on time. We also reviewed reports and presentations of WHO TB/HIV meetings that were conducted in [2003] [2004] [2005] [2006] [2007] [2008] [2009] . We used the framework of the six components (pillars) of the health system to present the key health system-related barriers for scaling up the implementation of IPT [31] .
Results and discussion
Global implementation of isoniazid preventive therapy Figure 1 shows the proportion of PLHIV among whom active TB was excluded so that IPT could be provided. Very few countries reported the provision of IPT and even those that reported the activity mostly provide it for less than 1% of PLHIV.
Barriers to scaling the implementation of IPT Barriers to the implementation of IPT are diverse and can occur from global to facility levels. Table 2 summarizes key health system-related barriers for scaling up the implementation of IPT listed by the six components (pillars) of the health system [31] .
Leadership and governance-related
The 1998 WHO and UNAIDS policy on IPT recommended the implementation of IPT with mandatory chest radiography to exclude active TB and a targeted approach for individuals with a positive TST result. However, noting TST is not feasible in most settings, the policy recommends IPT in populations with more than 30% prevalence of Mycobacterium tuberculosis infection and other target groups such as healthcare workers, household contacts of patients with TB, prisoners and miners [25] .
The number of countries that issued supportive policy for IPT implementation has progressively increased from 8 to 102 between 2002 and 2009. However, only 27-50% of those countries with supportive national policies actually reported the provision of IPT for PLHIV per year during the period [32] . This is a clear illustration of the gap between the existence of a policy and the actual implementation of IPT. Although there can be many reasons for this gap, some national policies can impede wider implementation of IPT. Such attitudes most likely emanate from the concerns by program managers and service providers of inadvertent monotherapy with INH for undetected TB that could give rise to the development of INH resistance.
The fear of development of drug-resistant TB is one of the reasons commonly cited among program managers and service providers for limited scaling up [33] . Studies demonstrated that there is no significant increased risk of INH monoresistance following IPT [34, 35] .
Service delivery-related
The TST is used to identify skin test positive persons who have latent TB infection and who would benefit from IPT, mainly in low TB incidence and high-income countries [36] . However, aside from its expense and difficulties with logistics, it has several known operational and technical limitations including poor specificity, crossreactivity with BCG (Bacillus Calmette-Guérin) vaccination and nontuberculosis mycobacteria, and poor reproducibility [37] . Implementation of TST requires well trained staff, and interpretation of the result requires a thorough experience and repeated visits by the patient [38] . Moreover, HIV-infected persons have a compromised ability to react to the skin test because of cutaneous anergy associated with immunosuppression [39] .
Studies reported that the numbers of PLHIV need to be treated with IPT in order to prevent one case of TB ranged from 6 to 70 depending on the incidence of TB at baseline, length of trial follow-up, and individual factors such as skin positivity for TST [14, 40, 41] . The commonly cited pooled number needed to treat for PLHIV with IPT to prevent one case of TB is 50, which lowers into 20 if the person is TST positive [14] . However, the interpretation of such pooled numbers need caution, as the baseline risk often varies appreciably among trials [42] . The data are based on routine reporting from the National AIDS and TB Control Programs of the countries. Although a standardized system is in place to ensure the validation of data collected, it is not always possible to obtain data from some countries consistently over the years because of lack of well established monitoring and evaluation system in some countries. Some countries (e.g., Malawi and Rwanda) stop the provision of isoniazid preventive therapy (IPT) due to a policy change after reporting the activity in earlier years. The timing and cycle of data collection was changed for 2009 in order to reduce the reporting gap into 1 year. Therefore, not all countries that reported the activity in 2008 were able to comply with the deadline. TB, tuberculosis. There are no studies that examined the effect of individual adherence to IPT on its efficacy at a population level. However, there are a few studies that examined the effect of adherence on individual outcome and measured adherence in different ways [12, 43, 44] . Number of clinic visits [43] , pill collection [45] , pill count [12] , and urine test [45] were used to measure adherence for IPT. Adherence rates for IPT vary significantly, and shorter duration of treatment and peer support were identified as factors that improve adherence [11, 12, 43, 44, 46] . Adherence is important for individuals to realize the full risk reduction benefit of isoniazid preventive treatment; however, given the low bacillary load should they stop their course of treatment it does not have the same implications as stopping treatment for TB.
Supplies and product-related
Existing global and national policies do not explicitly address the drug management INH for use as prophylaxis apart from stating that National TB Control Programs (NTP) should actively participate in drug logistics and procurement [25] . Being an anti-TB drug, INH is often under strict NTP control in those countries implementing the Stop TB Strategy. Anecdotal evidence suggests that this has resulted in no access to the drug for HIV implementers to procure quality INH to be used as a prophylaxis for PLHIV.
Health workforce-related
In clinical trials and clinical practice, IPT is well tolerated in PLHIV. The most serious adverse reaction is hepatotoxicity, which occurs in a very small proportion of individuals receiving treatment ranging between 0.001 and 0.004% [20, 47, 48] . The risk of hepatitis increases with age of more than 35 years [48, 49] . However, the benefits of IPT outweigh the risk of hepatitis in the presence of HIV infection in people with age of more than 35 years [50] . Similarly, the risk of hepatitis increases with excessive alcohol use [48] . Alcohol use was reported in 11% of PLHIV receiving 6-month IPT in Botswana [51] . Lack of experience, knowledge, and clarity on the benefits of IPT and existing guidelines by health workers were cited as important barriers for IPT provision rather than patient-related factors [52] .
Health information system-related
The monitoring and evaluation of collaborative TB/HIV activities, in which the provision of IPT is one critical component is important to provide the means to assess the quality, effectiveness, and coverage of services [30] . Not many resource-constrained countries have an established system to monitor and evaluate the implementation of collaborative TB/HIV activities, including the provision of IPT [53] . Furthermore, reporting requirements from donor agencies that are not harmonized with internationally and nationally agreed indicators and processes place unnecessary burden on programs [30, 54] .
Isoniazid preventive therapy for people living with HIV Getahun et al. S61 Health system financing-related Over the last decade, there has been an increased availability of funds particularly through the President's Emergency Plan for AIDS Relief (PEPFAR) [54] and the Global Fund to AIDS, TB and Malaria (GFATM) [55] for collaborative TB/HIV activities. However, the lack of national consensus and political commitment resulted in limited utilization of these funding opportunities to scale up IPT. There are reports that some countries requested for reprogramming of approved funds for scale up of IPT from the GFATM because of lack of national policy and consensus (unpublished communication, GFATM).
There are a number of studies that explored the costeffectiveness of IPT implementation. The provision of IPT for PLHIV resulted in monetary savings in medical care and social costs [56] . A study in South Africa concluded that IPT provision is cost saving after it was found that US$ 92-183 was needed for completing a 6-month course [57] . None of the studies took place in a population that is also on ART.
Solutions to promote nationwide scale-up of isoniazid preventive therapy implementation
Create a conducive national policy and program environment Implementation of IPT should be a priority for National AIDS control programs, not only in high HIV prevalent settings but also countries with concentrated or low-level HIV epidemics. Policies with national time bound targets are necessary to scale-up of implementation of IPT. This facilitates implementation and also helps to mobilize political commitment and engagement from TB and HIV stakeholders. Unequivocal endorsement of IPT, a clear direction, and bold leadership from the highest political level in government coordinating the country's AIDS response (e.g., National AIDS Commission) and the Ministry of Health are crucial to promote nationwide scale-up of IPT along with other collaborative TB/HIV activities.
Similarly, the development of a conducive operational environment needs to be prioritized. All national and local HIV training modules and training efforts need to include IPT as an essential element of providing HIV care and treatment and also to address misconceptions among service providers. Clear, simple and nonrestrictive operational guidelines should be developed.
Adopt the simplified symptom-based algorithm for tuberculosis screening and isoniazid preventive therapy provision WHO has revised its guidelines on IPT and recommends the use of a simplified screening algorithm that relies on the absence of all four clinical symptoms (current cough, night sweats, fever, and weight loss) to identify those PLHIV who have less likelihood of active TB disease and hence are eligible for IPT [58] . Chest radiography is no longer required as a mandatory investigation before starting IPT and TST is not a requirement for initiating IPT for PLHIV [58] . This simplified symptom-based algorithm should be used for all adults living with HIV, including pregnant women, people who are receiving ART, and those who successfully completed TB treatment [58] . It is worth noting that protective benefits of concomitant use of IPT with ART were demonstrated in two observational studies from Brazil [59] and South Africa [60] , and a subanalysis of an unpublished randomized clinical trial data from Botswana [15] .
Client monitoring and education
Client monitoring and education can reduce the risk of serious INH-related toxicity [49] . Clients should be warned about symptoms of INH toxicity (abdominal pain, nausea, and jaundice) and told to stop taking INH and return for evaluation if these occurs. They should also be warned about alcohol consumption while on IPT.
Monthly monitoring for symptoms is very effective, but may not be practical in all settings. PLHIV and receiving IPT should have regular clinical follow-up based on the national, local, and clinical context. This includes regular screening using the symptom-based algorithm at every contact with healthcare providers. Programs implementing IPT are encouraged to introduce national TB drug resistance surveillance systems in accordance with internationally agreed guidelines [61] .
Adherence to therapy is an important issue, and interventions to promote adherence may be very useful. Various incentives and enablers have been shown to improve adherence in diverse populations of people receiving IPT. Client education [48] is an effective strategy for increasing adherence. The use of a 300 mg INH formulation, and a fixed-dose combination of INH and co-trimoxazole, which is being explored might improve adherence as well. include INH as a TB prevention commodity for PLHIV as part of their core services.
Establish monitoring and evaluation systems
Functional and integrated monitoring and evaluation systems of IPT implementation that are in line with internationally recommended patient monitoring and evaluation systems [62] and harmonized indicators [30] are essential. Table 3 describes the standardized indicators for TB screening and IPT provision that should be adopted by HIV implementers. The indicator for TB screening measures the number of adults and children enrolled in HIV care (i.e., enrollment in the pre-ART register or in the ART register once started on ART) who had TB status assessed and recorded during their last visit, expressed as a proportion of all adults and children enrolled in HIV care in the reporting period. Even if PLHIV may be screened for TB several times during a given period of reporting, what should be reported is screening in their last contact or visit to the health worker or the facility. The ART and pre-ART registers included in the integrated patient monitoring and evaluation system enable the recording of assessment of TB status on a monthly basis over a 2-year period [62] . Similarly, the IPT indicator measures the number of adults and children newly enrolled in HIV care who are started on treatment with IPTexpressed as a proportion of the total number of adults and children newly enrolled in HIV care over a given time period. This is reported quarterly. Again both pre-ART and ART registers serve as a source for the data. HIV services implementing TB screening and IPToutside the facilities run by the government should embrace these important indicators along with others and set up a reporting mechanism in order to ensure their data are captured to inform the national monitoring and evaluation system. These steps will be useful to address the limitations of the existing data collection system, which may not capture all the implementation of IPT happening out there as the data are primarily coming through the National AIDS and TB Control Programs.
Meaningful engagement of affected communities
National AIDS and TB stakeholders should ensure successful and meaningful engagement of PLHIV and their communities in both planning and implementation of TB screening and IPT. Existing HIV literacy efforts need to mainstream information on TB prevention, diagnosis, and treatment, including TB screening and IPT. Global and national networks of PLHIV need to play a leadership role to ensure the visibility of TB prevention, diagnosis, and treatment services as part of their advocacy work both nationally and at the grass root level. PLHIV and their affected communities should be encouraged to consider IPT as an evidence-based effective intervention and should be empowered to demand IPT during their encounter with HIV service providers.
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To ensure that eligible HIV-positive individuals are given treatment for latent TB infection and thus to reduce the incidence of TB in people living with HIV. Periodicity Data are collected continuously and reported as part of the routine cross-sectional reports to national level. These data can be crosschecked during the annual patient monitoring review.
Collected continuously and reported and analyzed quarterly.
Responsibility National AIDS Control Program. National AIDS Control Program Measurement tools This indicator is collected from the pre-ART and ART registers and summarized on the cross-sectional quarterly reports. This indicator could also be assessed from a systematic sample of patient HIV care/ART cards during annual patient monitoring reviews.
Pre-ART register, aggregated on the cross-sectional quarterly report.
ART, antiretroviral treatment; TB, tuberculosis. Data from [30] .
a HIV care includes HIV treatment, that is, enrollment in the pre-ART register or in the ART register once started on ART.
Conclusion
IPT has been shown to be beneficial for PLHIV, but uptake has been slow for a number of reasons, including resource constraints and reluctance on the part of policy makers and program implementers. With the widespread establishment of HIV care and treatment programs, the opportunity exists to incorporate TB screening using a simple symptom-based clinical algorithm that will reliably identify PLHIV who can commence IPT or who will be investigated for TB or other illnesses. This approach calls for the abolition of the obsolete view of considering IPTas a stand-alone NTP-led TB intervention. IPT is primarily an HIV intervention, which should be a responsibility of National AIDS Programs, any HIV services, and primary care services where PLHIV seek care.
HIV services implementing TB screening and IPT should embrace standardized TB screening and IPT indicators, including the use of standardized pre-ART and ART registers [62] . If the implementation is outside the facilities run by the government, a reporting mechanism should be established in order to ensure data are captured by the national monitoring and evaluation system. Prevention of TB in this population will contribute to the overall goal of reducing global TB burden and improving the quality of life of PLHIV.
